Diagnosis and prognosis of neutrophil gelatinase-associated lipocalin for acute kidney injury with sepsis: a systematic review and meta-analysis by unknown
RESEARCH Open Access
Diagnosis and prognosis of neutrophil
gelatinase-associated lipocalin for acute
kidney injury with sepsis: a systematic
review and meta-analysis
An Zhang1†, Ying Cai1†, Peng-Fei Wang1, Jian-Ning Qu1, Zhen-Chun Luo1, Xiao-Dong Chen1, Bin Huang1, Yi Liu1,
Wen-Qi Huang1, Jing Wu1 and Yue-Hui Yin2*
Abstract
Background: Neutrophil gelatinase-associated lipocalin (NGAL) has been identified as an early biomarker for
prediction of acute kidney injury (AKI). However, the utility of NGAL to predict the occurrence of AKI in septic
patients remains controversial. We performed a systematic review and meta-analysis to evaluate the evidence on
diagnosis of sepsis AKI and the prediction of other clinical outcomes.
Method: The MEDLINE, EMBASE, Cochrane Library, Wanfang, and CNKI databases were systematically searched up
to August 19, 2015. Quality assessment was applied by using the Quality Assessment for Studies of Diagnostic
Accuracy (QUADAS-2) tool. The diagnostic performance of NGAL for the prediction of AKI in sepsis was evaluated
using pooled estimates of sensitivity, specificity, likelihood ratio, and diagnostic odds ratio (DOR), as well as
summary receiver operating characteristic curves (SROC).
Results: Fifteen studies with a total of 1,478 patients were included in the meta-analysis. For plasma NGAL, the
pooled sensitivity and specificity with corresponding 95 % confidence intervals (CI) were 0.83 (95 % CI: 0.77 − 0.88)
and 0.57 (95 % CI: 0.54 − 0.61), respectively. The pooled positive likelihood ratio (PLR) was 3.10 (95 % CI: 1.57 − 6.11)
and the pooled negative likelihood ratio (NLR) was 0.24 (95 % CI: 0.13 − 0.43). The pooled DOR was 14.72 (95 % CI:
6.55 − 33.10) using a random effects model. The area under the curve (AUC) for SROC to summarize diagnostic
accuracy was 0.86. For urine NGAL, the pooled sensitivity, specificity, PLR, NLR, DOR, and AUC values were 0.80
(95 % CI: 0.77 − 0.83), 0.80 (95 % CI: 0.77 − 0.83), 4.42 (95 % CI: 2.84 − 6.89), 0.21 (95 % CI: 0.13 − 0.35), 24.20
(95 % CI: 9.92 − 59.05) and 0.90, respectively. Significant heterogeneity was explored as a potential source.
There was no notable publication bias observed across the eligible studies. NGAL for prediction of renal
replacement therapy (RRT) and mortality associated with AKI in septic patients were also evaluated.
Conclusion: To a certain extent, NGAL is not only an effective predictive factor for AKI in the process of
sepsis, but also shows potential predictive value for RRT and mortality. However, future trials are needed to
clarify this controversial issue.
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Background
Acute kidney injury (AKI) is a widespread problem in
critically ill patients, with a high and rapidly increasing
incidence, particularly in the ICU, as a potentially life-
threatening factor associated with significant morbidity
and mortality [1, 2]. Sepsis is a well-known precipitating
factor for the development of AKI, accounting for al-
most half of all such cases [3, 4]. The diagnosis of AKI
relies on serum creatinine according to the guidelines
without reflection of kidney damage. Early accurate pre-
diction and intervention in the initial periods of AKI in
sepsis play a critical role in improving the prognosis of
the disease. Neutrophil gelatinase-associated lipocalin
(NGAL), a member of the lipocalin superfamily that is
expressed by neutrophils and various epithelial cells [5],
is one of the most frequently investigated and a rapidly
emerging biomarker for early prediction of different
clinical settings of AKI [6]. Along with the deepening
understanding, similar studies have also gradually in-
creased the accuracy of prediction of sepsis-induced
AKI. However, it remains controversial whether NGAL
is a predictive biomarker of early AKI in septic pa-
tients because of the lack of corresponding statistical
data. Therefore, in view of this confusion, we per-
formed a systematic review and meta-analysis to evalu-
ate the evidence on diagnosis of sepsis AKI to predict
clinical outcomes of renal replacement therapy (RRT)
and mortality.
Methods
This systematic review was based on previous published
studies, thus no ethical approval and patient consent
were required.
Study search strategy
Two investigators (P-FW and YL) systematically and in-
dependently searched the MEDLINE (via PubMed inter-
face), EMBASE, Cochrane Library, Wanfang, and CNKI
(China National Knowledge Infrastructure) databases
to 19 August 2015. Also, additional studies were evalu-
ated by reviewing the reference lists and hand-
searching bibliographies of relevant articles. The litera-
ture search included the keywords and MeSH terms
“neutrophil gelatinase-associated lipocalin,” “NGAL,”
“sepsis,” “severe sepsis,” and “septic shock,” with no
language restrictions.
Study selection
Two of the investigators (P-FW and YL) independently
determined study eligibility by reviewing each of the ci-
tations and retrieving the literature by titles or abstracts,
and subsequently the full texts. Any difference in opin-
ion regarding eligibility was resolved through consensus
with an arbitrator (AZ). The studies were included in
this review if they met the following set of inclusion cri-
teria: human studies with participants ≥18 years of age;
plasma/serum or urine NGAL for prediction of AKI in
septic patients or prediction of RRT or mortality in sep-
tic patients with AKI (including patients of sepsis with
AKI and non-AKI); included a total number of at least
40 septic patients; and the American College of Chest
Physicians/Society of Critical Care Medicine (ACCP/
SCCM) [7], Society of Critical Care Medicine/European
Society of Intensive Care Medicine/American College of
Chest Physicians/American Thoracic Society/Surgical
Infection Society (SCCM/ESICM/ACCP/ATS/SIS) [8],
or “Survival Sepsis Campaign 2012” [9] consensus
criteria as a reference standard for defining sepsis and
the Risk, Injury, Failure, Loss, End-Stage Kidney Disease
(RIFLE) [10], Acute Kidney Injury Network (AKIN)
[11], or Kidney Disease Improving Global Outcomes
(KDIGO) [12] creatinine criteria for defining AKI.
Studies were excluded if they: focused on chronic kid-
ney disease, or renal transplantation, etc.; were dupli-
cate articles describing the same study; were articles
not based on original studies, such as reviews, com-
mentaries, conference abstracts, letters, supplementary
issues, poster presentations, or editorials; and con-
tained insufficient information.
Data extraction and quality assessment
Two reviewers (P-FW and YL) independently extracted
prespecified data elements from each trial, including the
request for documentation and recalculation of the fol-
lowing variables: first author, year of publication, study
location, study design, admission setting, definitions of
AKI and sepsis, sampling time, and method for NGAL
measurement using a standardized data extraction form.
Also, the diagnostic test performed, the area under the
curve (AUC), optimal cutoff thresholds, sensitivity, spe-
cificity, and number of AKI and non-AKI septic patients
were obtained from the enrolled articles. Absolute data
of true-positive (TP), false-positive (FP), true-negative
(TN) and false-negative (FN) rates or equivalent data
were provided or could be calculated for constructing
2 × 2 contingency tables. If only the AUC data without a
2 × 2 table data were included, we contacted the corre-
sponding authors by email and asked whether they were
willing to share their unpublished data in the articles for
inclusion in the present study. If no reply was received,
the study was excluded from the meta-analysis and in-
cluded in the descriptive analysis only. We attempted to
extract data to evaluate the prediction of RRT and mor-
tality of AKI among septic patients. However, since these
data were rarely reported in the studies, we only in-
cluded a simple description in the subsequent analysis.
Two reviewers (J-NQ and W-QH) independently
assessed the methodological quality of the studies using
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the Quality Assessment of Diagnostic Accuracy Studies
2 (QUADAS-2) tool for quality assessment and accuracy
of diagnostic studies [13]. The QUADAS-2 tool is based
on four key domains: patient selection, index test, refer-
ence standard, and flow and timing. “Risk of bias” and
“concerns regarding applicability” were evaluated for all
four domains and the first three domains, respectively,
with each item judged as “yes,” “no,” or “unclear.” To
judge the “risk of bias,” if the answers to all signaling
questions were “yes” in a domain, the domain was
judged as having a low risk of bias. Any signaling ques-
tion that was answered “no” indicated a high risk of bias.
The judgment principle of “applicability” was the same
as the bias section, but without signaling questions.
Statistical analysis
TP, TN, FP, and FN rates for each test in every study
were analyzed using Meta-DiSc (version 1.4) software, as
described elsewhere [14], to assess the sensitivity, specifi-
city, positive likelihood ratio (PLR), negative likelihood
ratio (NLR), and diagnostic odds ratio (DOR) for each
included study. The summary measures were calculated
using a random effects model (DerSimonian and Laird
method) for high heterogeneity, otherwise a fixed effect
model was chosen (Mantel −Haenszel method). Forest
plots of accuracy indexes were also constructed. To
describe the relationship between test sensitivity and
specificity, a summary receiver operating characteristics
(SROC) curve was constructed based on TP and FP
rates. The AUC was calculated as an overall summary
index to measure the diagnostic performance for the
prediction of AKI in septic patients by NGAL, which has
been defined as a useful risk predictor when AUC ≥0.70
[15]. The Q* index is defined as the closest point to the
idea top-left corner on the SROC curve where sensitivity
equals specificity [16]. A threshold effect is an important
cause of heterogeneity in diagnostic testing that can be
observed as a typical pattern of a “shoulder-arm” shape
in the SROC plane and confirmed by the Spearman cor-
relation coefficient and probability (P) value between the
logit of sensitivity and logit of 1 – specificity. P <0.05 in-
dicated the existence of a threshold effect [17]. Hetero-
geneity caused by nonthreshold effects was assessed by
applying the Cochran’s Q test and the I2 index. For the
former, it is considered that more such studies will be
homogeneous when the statistical significance is set
at P >0.10, according to a chi-squared distribution
with k – 1 degrees of freedom [18]. The I2 index was
used to measure the degree of heterogeneity between
multiple studies. I2 values <25 %, of 25–50 %, and >50 %
indicated modest, moderate, and substantial heterogen-
eity, respectively. Likelihood ratios state how many times
more likely particular test results would be accurate
for patients with disease than for subjects without
disease [19].
In order to eliminate factors that influence heterogen-
eity, sensitivity analysis was conducted to examine the
stability by omitting one study at a time. Meta-
regression and subgroup analyses were also performed
to identify factors that contributed to heterogeneity. The
heterogeneity test, assessment of threshold effect, diag-
nostic performance, as well as meta-regression and sub-
group analyses were also performed using Meta-DiSc
(version 1.4) software [14]. In addition, publication bias
was assessed with the Deeks test using Stata (version
12.0) statistical software (STATA Corporation, College
Station, TX, USA) when >10 studies were evaluated [20].
Results
Study characteristics and quality assessment
The initial search identified 551 relevant articles from
various databases, of which 113 were excluded because
of duplication. Of the remaining 438 studies, 342 were
excluded after screening the titles and abstracts. After
screening the full texts, 75 studies were excluded in ac-
cordance with the eligibility criteria. Eligibility of the
remaining 21 studies was assessed. Among these, 15
studies [21–35] that included 1478 patients published
between 2010 and 2015 were included for meta-analysis
for prediction of AKI in septic patients. The included
studies were geographically diverse: four studies were
conducted in Europe, two in America, and the remaining
studies were of Asia origin. Of the 21 studies, 10 included
descriptive analysis of the prediction AKI in septic patients
and RRT or mortality in sepsis-induced AKI without 2 × 2
table data. A flowchart depicting the literature screening
method is shown in Fig. 1. The main features and detailed
information of each study included for the meta-analysis
are presented in Table 1, and the quality assessment of the
included 15 studies is presented in Table 2.
Diagnostic performance
NGAL for prediction of AKI in septic patients
Plasma NGAL Six studies [24, 26, 29, 31, 33, 34] enrol-
ling 433 patients investigated the predictive value of
plasma NGAL as a biomarker of AKI in septic patients.
The key results of these studies are summarized in
Table 3. The pooled sensitivity and specificity were 0.83
(95 % confidence interval (CI): 0.77–0.88) and 0.57
(95 % CI: 0.54 − 0.61), respectively. The pooled PLR was
3.10 (95 % CI: 1.57 − 6.11) and the pooled NLR was 0.24
(95 % CI: 0.13 − 0.43) (Fig. 2). The pooled DOR was
14.72 (95 % CI: 6.55 − 33.10) using a random effects
model. We performed SROC to summarize the diagnosis
accuracy: the AUC was 0.86 (standard error (SE) = 0.04)
with Q* of 0.79 (SE = 0.04), indicating good, but not ex-
cellent, diagnostic accuracy (see Fig. 4).
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Four studies lacked 2 × 2 contingency table data for the
meta-analysis, but included AUC prediction values for a
brief description. In an observational study of septic pa-
tients admitted to the emergency room (ER) [36], the
AUC of serum NGAL for prediction of AKI in septic pa-
tients was 0.90 (95 % CI: 0.85–0.94), greater than that of
procalcitonin. In another observational retrospective
study [37], the diagnostic accuracy of plasma NGAL for
prediction of AKI among the 101 consecutive investi-
gated septic patients admitted to the ER had an AUC of
0.80. Yamashita et al. [38] reported predominantly high
AUCs of 0.94 (95 % CI: 0.88–0.97) and 0.92 (95 % CI:
0.84–0.96) for plasma NGAL to predict AKI and severe
AKI in septic patients, respectively. When NGAL was
combined with the clinical model, the AUC was 0.89
(95 % CI: 0.77–0.95), slightly better than with only a
clinical model (0.87; 95 % CI: 0.76–0.94) for detecting
severe AKI in septic patients. Dai et al. [39] showed
that the AUC of plasma NGAL was 0.83 (95 % CI:
0.74 − 0.92), indicating that NGAL was a good indicator of
the occurrence of AKI at 24 hours in septic patients.
There was no notable threshold effect in the six stud-
ies included in the meta-analysis. Given the small sample
size of most of the included studies, we did not conduct
meta-regression or subgroup analyses, although we per-
formed sensitivity analysis to eliminate factors that influ-
ence heterogeneity by omitting each one study at a time.
The pooled AUC estimated by the remaining studies did
not change significantly, with the exception of one of the
studies (Table 4). After removing that study [29], sensi-
tivity was 0.87 (95 % CI: 0.81–0.92), specificity was 0.55
(95 % CI: 0.51–0.59), PLR was 3.33 (95 % CI: 1.23–9.03),
NLR was 0.20 (95 % CI: 0.13–0.30), DOR was 22.13
(95 % CI: 11.20 − 43.73), and the AUC reached 0.90.
These changes might be related to the study that was a
substudy of the 6S trial (6S—Scandinavian Starch for
Severe Sepsis/Septic Shock trial) [40]. The 6S trial com-
pared the effect of hydroxyethyl starch 130/0.4 with
Ringer’s acetate or Ringer’s acetate alone on kidney fail-
ure in patients with severe sepsis. The differences in
fluid resuscitation might have led to the potential het-
erogeneity. With the exception of this study, no other
n=342
Fig. 1 Study flow diagram. *Several distinct but valid data were extracted from one single literature item (a total number of 10 literatures), in
which multiple endpoints in clinical trials were incorporated. AKI acute kidney injury, AUC area under the curve, NGAL neutrophil gelatinase-
associated lipocalin, RRT renal replacement therapy
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Table 1 Characteristics of included studies for NGAL to predict AKI in septic patients
Study Location Design Setting AKI definition Sepsis definition Source AKI/ sepsis (n) Sampling time
(hours)
Storage (°C) NGAL assay NGAL test kits
Aydogdu et al. [21] Turkey PC ICU RIFLE SCCM/ESICM/ACCP/
ATS/SIS
Urine 63/129 NR −80 ELISA Biovendor (Brno, Southern
Moravia, Czech Republic)
Camou et al. [31]
(ClinicalTrials.gov NCT01122225)
France PC ICU RIFLE or AKIN SCCM/ESICM/ACCP/
ATS/SIS
Plasma 43/50 Admission NR ELISA Triage (Biosite Inc., San Diego,
CA, USA)
de Geus et al. [34] Netherlands PC ICU AKIN ACCP/ SCCM Plasma 50/75 Admission −80 ELISA Triage (Biosite Inc.)
Fan et al. [30] China PC ICU RIFLE SCCM/ESICM/ACCP/
ATS/SIS
Urine 58/126 Peak NR RIA –
Hjortrup et al. [29]
(ClinicalTrials.gov NCT00962156)
Denmark PC ICU KDIGO ACCP/SCCM Plasma 31/124 Admission −80 PETIA BioProto Diagnostics A/S
(Gentofte, Denmark)
Urine 25/100 −24
Li and Xu [22] China PC ICU AKIN ACCP/SCCM Urine 17/74 24 −20 ELISA R&D Systems (Minneapolis,
MN, USA)
Martensson et al. [33] Sweden NR ICU RIFLE or AKIN ACCP/SCCM Plasma 18/45 12 NR RIA –
Urine 18/45 NR RIA –
Niu et al. [23] China PC ER AKIN SCCM/ESICM/ACCP/
ATS/SIS
Urine 26/60 12 −80 ELISA Hycult Biotech (Uden, North
Brabant, The Netherlands)
Shapiro et al. [24] USA PC ER RIFLE ACCP/SCCM Plasma 24/66 Admission −70 ELISA Triage (Biosite Inc.)
Si et al. [32] Brazil PC ER AKIN SSC Urine 47/168 Admission −80 ELISA NR
Wang et al. [25] China NR ICU KDIGO ACCP/SCCM Urine 33/87 48a −80 ELISA R&D Systems
Xing et al. [26] China NR ICU AKIN SCCM/ESICM/ACCP/
ATS/SIS
Plasma 35/73 NR −80 ELISA R&D Systems
Urine 35/73 −20 ELISA R&D Systems
Yan et al. [27] China NR ICU AKIN ACCP/SCCM Urine 57/112 2 −80 ELISA R&D Systems
Yan and Zang [28] China PC ICU AKIN SCCM/ESICM/ACCP/
ATS/SIS
Urine 44/141 8 −80 ELISA R&D Systems
Zhou et al. [35] China NR ICU AKIN SCCM/ESICM/ACCP/
ATS/SIS
Urine 46/148 8 −80 ELISA R&D Systems
aForty-eight hours before AKI
ACCP/SCCM American College of Chest Physicians/Society of Critical Care Medicine, AKI acute kidney injury, AKIN Acute Kidney Injury Network, ELISA enzyme-linked immunosorbent assay, ER emergency room, KDIGO
Kidney Disease: Improving Global Outcomes, NGAL neutrophil gelatinase-associated lipocalin, NR not reported, PC prospective cohort, PETIA particle-enhanced turbidimetric immunoassay, RIA radioimmunoassay, RIFLE
Risk, Injury, Failure, Loss, End-Stage Kidney Disease, SSC Survival Sepsis Campaign, SCCM/ESICM/ACCP/ATS/SIS Society of Critical Care Medicine/European Society of Intensive Care Medicine/American College of Chest









individual study significantly influenced the meta-
analysis results, thereby indicating a certain credibility of
the outcomes.
Urine NGAL For urine NGAL, 12 studies [21–23, 25–
30, 32, 33, 35] enrolling 1263 persons were included in
the pooled diagnostic assessment of performance. The
key results of these studies are summarized in Table 3.
The pooled sensitivity and specificity were 0.80 (95 % CI:
0.77 − 0.83) and 0.80 (95 % CI: 0.77 − 0.83), respectively.
The pooled PLR was 4.42 (95 % CI: 2.84 − 6.89) and the
pooled NLR was 0.21 (95 % CI: 0.13 − 0.35) (Fig. 3). The
pooled DOR was 24.20 (95 % CI: 9.92 − 59.05). The AUC
was 0.90 (SE = 0.02) with Q* of 0.84 (SE = 0.02) (Fig. 4).
Meanwhile, Yamashita et al. and Dai et al. also reported
the usefulness of urine NGAL to predict septic AKI with
AUCs of 0.84 (95 % CI: 0.72 − 0.91) and 0.88 (95 % CI:
0.79–0.95), respectively [38, 39].
Considering the heterogeneity across these 12 eligible
studies and exclusion of the threshold effect, we per-
formed subgroup analysis between different study char-
acteristics. The admission setting (ICU or ER), study
design (prospective or nonprospective), number of cases
(n ≥100 or n <100), NGAL test method (enzyme-linked
immunosorbent assay (ELISA) or non-ELISA), location
of the subjects (Asia or others), and publication language
(English or Chinese) were hypothesized as possible fac-
tors influencing heterogeneity. The results of the sub-
group analysis are presented in Table 5. Univariate
meta-regression was also performed with these factors
to explore the sources of heterogeneity. However, causes
of heterogeneity could not be explained with P <0.05
(Table 5). In addition, the Deeks funnel plot indicated
the absence of notable publication bias (P = 0.132)
(Fig. 5).
NGAL for prediction of RRT in septic patients with AKI
A recent study reported that plasma and urine NGAL
had relatively low predictive values for use of RRT in
ICU patients with severe sepsis and, even excluding pa-
tients with chronic kidney disease, the AUCs were 0.73
(95 % CI: 0.61–0.85; P = 0.64) and 0.68 (95 % CI: 0.53–
0.83; P = 0.52), respectively [29]. In another study enrol-
ling 126 septic patients, 23 of 58 patients with septic
AKI received RRT. The peak urine NGAL was higher in
patients receiving hemodialysis compared with those not
Table 2 Quality assessment of included eligible studies using QUADAS-2
low risk, high risk, unclear risk, p plasma, u urine
1 unknown whether a consecutive or random sample of patients enrolled, 2 unknown whether the index test results interpreted without knowledge of the results
of the reference standard or unknown whether the threshold was prespecified, 3 unclear whether the reference standard results were interpreted without
knowledge of the results of the index test, 4 unknown whether all patients were included in the analysis, # unknown whether enrolling a consecutive or random
sample without introduction
QUADAS-2 Quality Assessment of Diagnostic Accuracy Studies 2
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receiving hemodialysis (median, 456 vs. 341 ng/ml, re-
spectively; P <0.0001). The AUC of the peak urine
NGAL for prediction of hemodialysis was 0.77 (95 % CI:
0.64–0.83) with a cutoff level of 494 ng/ml and the sen-
sitivity and specificity were 0.89 and 0.71, respectively
[30]. The results of a subgroup study of septic AKI
patients with community-acquired pneumonia who met
the RIFLE-F criteria found that plasma NGAL was a
poor predictor for the requirement of RRT (AUC 0.62,
95 % CI: 0.45 − 0.81) [41]. In 50 critically ill adults with
septic shock, 86 % had AKI and 30 % required RRT dur-
ing their ICU stay. The AUC of plasma NGAL for
Table 3 Diagnostic value of NGAL to predict AKI in septic patients in individual studies





TP rate FP rate FN rate TN rate
Aydogdu et al. [21] 0.80 NR 29.5 ng/ml 0.88 0.73 55 18 8 48
Camou et al. [31] 0.90 NR 150 ng/ml 0.93 0.44 40 4 3 3
de Geus et al. [34] 0.80 0.69–0.88 304 ng/ml 0.8 0.80 40 5 10 20
Fan et al. [30] 0.86 0.81-0.93 NR 0.89 0.74 52 18 6 50
Hjortrup et al. [29] (p) 0.66 0.54–0.77 NR 0.58 0.76 18 22 13 71
Hjortrup et al. [29] (u) 0.71 0.59–0.82 NR 0.56 0.72 14 21 11 54
Li and Xu [22] 0.94 0.68-0.97 50 μg/l 0.94 0.88 16 7 1 50
Martensson et al. [33] (p) 0.85 0.39-0.94 >120 ng/ml 0.83 0.86 15 4 3 23
Martensson et al. [33] (u) 0.86 0.68-1.00 >68 ng/mg.scr 0.71 1.00 13 0 5 27
Niu et al. [23] 0.91 NR 52 μg/g · scr 0.88 0.87 23 5 3 29
Shapiro et al. [24] 0.82 0.76-0.88 NR 0.96 0.51 23 312 1 325
Si et al. [32] 0.73 0.64-0.82 3.36 ng/ml 0.63 0.46 76 25 45 22
Wang et al. [25] 0.81 0.71-0.91 150 ng/ml 0.79 0.90 26 5 7 49
Xing et al. [26] (p) 0.86 0.77-0.94 92.5 ng/ml 0.85 0.87 30 5 5 33
Xing et al. [26] (u) 0.93 0.88-0.93 118.5 ng/ml 0.93 0.89 32 4 3 34
Yan et al. [27] 0.93 0.88-0.98 65 μg/l 0.95 0.86 54 8 3 47
Yan and Xang [28] 0.86 0.70-0.96 90 μg/l 0.87 0.86 38 14 6 83
Zhou et al. [35] 0.80 0.7 l-0.93 85 ng/l 0.78 0.80 36 20 10 82
AKI acute kidney injury, AUC area under the curve, CI confidence interval, FP false-positive, FN false-negative, NGAL neutrophil gelatinase-associated lipocalin, NR
not reported, p plasma, TP true-positive, TN true-negative, u urine
Specificity
0 .2 .4 .6 .8 1
Camou 2013 0.43    (0.10 - 0.82)
de Geus 2013 0.80    (0.59 - 0.93)
Hjortrup 2015 0.76    (0.66 - 0.85)
Martensson 2010 0.85    (0.66 - 0.96)
Shapiro 2010 0.51    (0.47 - 0.55)
Xing 2013 0.87    (0.72 - 0.96)
Specificity (95% CI)
Pooled Specificity = 0.57 (0.54 to 0.61)
Chi-square = 56.72; df =  5 (p = 0.0000)
Inconsistency (I-square) = 91.2 %
Sensitivity
0 .2 .4 .6 .8 1
Camou 2013 0.93    (0.81 - 0.99)
de Geus 2013 0.80    (0.66 - 0.90)
Hjortrup 2015 0.58    (0.39 - 0.75)
Martensson 2010 0.83    (0.59 - 0.96)
Shapiro 2010 0.96    (0.79 - 1.00)
Xing 2013 0.86    (0.70 - 0.95)
Sensitivity (95% CI)
Pooled Sensitivity = 0.83 (0.77 to 0.88)
Chi-square = 18.67; df =  5 (p = 0.0022)
Inconsistency (I-square) = 73.2 %
Positive LR
0.01 100.01
Camou 2013 1.63    (0.85 - 3.11)
de Geus 2013 4.00    (1.80 - 8.87)
Hjortrup 2015 2.45    (1.53 - 3.94)
Martensson 2010 5.63    (2.22 - 14.23)
Shapiro 2010 1.96    (1.74 - 2.20)
Xing 2013 6.51    (2.85 - 14.91)
Positive LR (95% CI)
Random Effects Model
Pooled Positive LR = 3.10 (1.57 to 6.11)
Cochran-Q = 52.43; df =  5 (p = 0.0000)
Inconsistency (I-square) = 90.5 %
Tau-squared = 0.6061 Negative LR
0.01 100.01
Camou 2013 0.16    (0.04 - 0.65)
de Geus 2013 0.25    (0.14 - 0.45)
Hjortrup 2015 0.55    (0.36 - 0.84)
Martensson 2010 0.20    (0.07 - 0.56)
Shapiro 2010 0.08    (0.01 - 0.56)
Xing 2013 0.16    (0.07 - 0.37)
Negative LR (95% CI)
Random Effects Model
Pooled Negative LR = 0.24 (0.13 to 0.43)
Cochran-Q = 14.48; df =  5 (p = 0.0129)




Fig. 2 Sensitivity a, specificity b, PLR c and NLR d of plasma NGAL for prediction of AKI in sepsis. CI confidence interval, LR likelihood ratio
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predicting RRT in septic AKI patients was 0.80, with an
optimal cutoff level of 348 ng/ml (sensitivity, 0.93; speci-
ficity, 0.68) [31].
NGAL for prediction of mortality in septic patients with
AKI
In a prospective observational study enrolling 92 septic
patients with AKI, the AUC of urine NGAL for the pre-
diction of 180-day mortality was 0.76 (95 % CI: 0.66–
0.86; P = 0.000), with an Acute Physiology and Chronic
Health Evaluation (APACHE) II score of 0.81 (95 % CI:
0.72–0.90; P = 0.00), higher than for serum creatinine
(0.64; 95 % CI: 0.52–0.76; P = 0.022). The AUCs of urine
NGAL and APACHE II scores were consistent with the
results of multivariate Cox regression analysis, showing
that urine NGAL (P = 0.014) and APACHE II score
(P = 0.015) were independent predictors of 180-day
mortality [42].
For severe sepsis, plasma and urine NGAL had poor
predictive values for 90-day mortality, and when com-
bined with plasma creatinine the AUCs were 0.55 (95 %
CI: 0.47 − 0.63) and 0.61 (95 % CI: 0.42 − 0.58), respect-
ively, with optimal cutoff values of 641 and 1687 ng/ml,
respectively. There were no notable differences in these
AUCs when compared with plasma creatinine alone
(AUC = 0.50) [29]. In a set of specific groups of septic
AKI patients with community-acquired pneumonia who
met the RIFLE-F criteria, the AUC of plasma NGAL for
Table 4 Pooled AUC and 95 % CI after omitting each trial in the meta-analysis (sensitivity analysis)
Study Sensitivity Specificity Positive likelihood ratio Negative likelihood ratio Diagnostic odds ratio AUC
(95 % CI) (95 % CI) (95 % CI) (95 % CI) (95 % CI)
Total 0.83 (0.77–0.88) 0.57 (0.54–0.61) 3.10 (1.57–6.11) 0.24 (0.13–0.43) 14.72 (6.55–33.10) 0.86
Camou et al. [31] 0.80 ( 0.73–0.86) 0.58 (0.54–0.61) 3.59 (1.45–8.88) 0.25 (0.13–0.48) 15.93 (6.21–40.85) 0.87
de Geus et al. [34] 0.83 (0.77–0.89) 0.57 (0.53–0.60) 2.94 (1.45–5.93) 0.22 (0.10–0.50) 14.98 (5.37–41.80) 0.86
Hjortrup et al. [29] 0.87 (0.81–0.92) 0.55 (0.51–0.59) 3.33 (1.23–9.03) 0.20 (0.13–0.30) 22.13 (11.20–43.73) 0.90
Martensson et al. [33] 0.83 (0.76–0.88) 0.57 (0.53–0.60) 2.78 (1.43–5.41) 0.24 (0.12–0.48) 13.27 (5.35–32.93) 0.85
Shapiro et al. [24] 0.81 (0.74–0.86) 0.79 (0.72–0.85) 3.34 (1.98–5.64) 0.26 (0.15–0.47) 14.03 (5.66–34.77) 0.86
Xing et al. [26] 0.82 (0.75–0.87) 0.56 (0.52–0.60) 2.63 (1.51–4.59) 0.26 (0.14–0.50) 11.38 (5.11–25.31) 0.83
AUC area under the curve, CI confidence interval
Specificity
0 .2 .4 .6 .8 1
Aydogdu 2013 0.73    (0.60 - 0.83)
Fan 2014 0.74    (0.61 - 0.83)
Hjortrup 2015 0.72    (0.60 - 0.82)
Li 2010 0.88    (0.76 - 0.95)
Martensson 2010 1.00    (0.87 - 1.00)
Niu 2015 0.85    (0.69 - 0.95)
Si 2015 0.47    (0.32 - 0.62)
Wang 2014 0.91    (0.80 - 0.97)
Xing 2013 0.89    (0.75 - 0.97)
Yan 2011 0.85    (0.73 - 0.94)
Yan 2013 0.86    (0.77 - 0.92)
Zhou 2014 0.80    (0.71 - 0.88)
Specificity (95% CI)
Pooled Specificity = 0.80 (0.77 to 0.83)
Chi-square = 57.09; df =  11 (p = 0.0000)
Inconsistency (I-square) = 80.7 %
Positive LR
0.01 100.01
Aydogdu 2013 3.20    (2.13 - 4.80)
Fan 2014 3.39    (2.26 - 5.08)
Hjortrup 2015 2.00    (1.21 - 3.31)
Li 2010 7.66    (3.79 - 15.49)
Martensson 2010 39.79   (2.51 - 629.87)
Niu 2015 6.02    (2.65 - 13.68)
Si 2015 1.18    (0.87 - 1.60)
Wang 2014 8.51    (3.62 - 19.98)
Xing 2013 8.69    (3.42 - 22.07)
Yan 2011 6.51    (3.42 - 12.40)
Yan 2013 5.98    (3.63 - 9.85)
Zhou 2014 3.99    (2.62 - 6.08)
Positive LR (95% CI)
Random Effects Model
Pooled Positive LR = 4.42 (2.84 to 6.89)
Cochran-Q = 83.33; df =  11 (p = 0.0000)
Inconsistency (I-square) = 86.8 %
Tau-squared = 0.4787 Negative LR
0.01 100.01
Aydogdu 2013 0.17    (0.09 - 0.34)
Fan 2014 0.14    (0.07 - 0.30)
Hjortrup 2015 0.61    (0.38 - 0.97)
Li 2010 0.07    (0.01 - 0.45)
Martensson 2010 0.29    (0.15 - 0.60)
Niu 2015 0.14    (0.05 - 0.40)
Si 2015 0.79    (0.54 - 1.17)
Wang 2014 0.23    (0.12 - 0.45)
Xing 2013 0.10    (0.03 - 0.28)
Yan 2011 0.06    (0.02 - 0.19)
Yan 2013 0.16    (0.08 - 0.34)
Zhou 2014 0.27    (0.15 - 0.47)
Negative LR (95% CI)
Random Effects Model
Pooled Negative LR = 0.21 (0.13 to 0.35)
Cochran-Q = 69.82; df =  11 (p = 0.0000)
Inconsistency (I-square) = 84.2 %
Tau-squared = 0.6422
Sensitivity
0 .2 .4 .6 .8 1
Aydogdu 2013 0.87    (0.77 - 0.94)
Fan 2014 0.90    (0.79 - 0.96)
Hjortrup 2015 0.56    (0.35 - 0.76)
Li 2010 0.94    (0.71 - 1.00)
Martensson 2010 0.72    (0.47 - 0.90)
Niu 2015 0.88    (0.70 - 0.98)
Si 2015 0.63    (0.54 - 0.71)
Wang 2014 0.79    (0.61 - 0.91)
Xing 2013 0.91    (0.77 - 0.98)
Yan 2011 0.95    (0.85 - 0.99)
Yan 2013 0.86    (0.73 - 0.95)
Zhou 2014 0.78    (0.64 - 0.89)
Sensitivity (95% CI)
Pooled Sensitivity = 0.80 (0.77 to 0.83)
Chi-square = 52.44; df =  11 (p = 0.0000)





Fig. 3 Sensitivity a, specificity b, PLR c and NLR d of urine NGAL for prediction of AKI in sepsis. CI confidence interval, LR likelihood ratio
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prediction of 90-day mortality was 0.71 (95 % CI: 0.66–
0.81), with an optimal cutoff value of 257 ng/ml [41].
In an observational retrospective study, plasma NGAL
(AUC = 0.69) predicted the mortality in these sepsis pa-
tients within 7 days after admission to the ER, stronger
than creatinine clearance (AUC = 0.61) but lower than
the APACHE II score (AUC = 0.75) [37]. Likewise, the
AUC of serum NGAL for predicting 28-day mortality in
septic patients was 0.83 (95 % CI: 0.85–0.94) with a cut-
off value of 236.62 ng/ml (sensitivity, 0.72; specificity,
0.77) [36].
Among 168 septic patients admitted to the ER, 72 %
developed AKI. Urine NGAL during the first 24 hours
after admission was a poor predictor of morbidity and
mortality (AUC = 0.66 and 0.68, respectively), whereas
urine NGAL (between 24 and 48 hours after admission)
was a better predictor (AUC = 0.70 and 0.81, respect-
ively) [32].
Discussion
Sepsis is a major contributing factor to AKI in hospital-
ized patients, especially among those with critical ill-
nesses [43, 44]. NGAL is among the most extensively
researched biological markers for early prediction of
AKI in both blood and urine specimens. Haase-Fielitz
et al. [45] performed a systematic review and identi-
fied 58 articles that enrolled >16,500 patients, and
found that both plasma and urine NGAL were pre-
dictive of AKI and its severity, with overall AUCs
ranging from 0.79 to 0.87 in different clinical settings.
However, it remains controversial whether NGAL is
predictive of AKI in septic patients because of the
lack of corresponding statistical data. The information
on NGAL for prediction of RRT and mortality in AKI
patients with sepsis was extremely limited. We systematic-
ally reviewed studies on the diagnostic accuracy of plasma
and urine NGAL for prediction of AKI in septic patients.
The pooled results indicated that plasma and urine NGAL
showed good diagnostic precision of AKI with sepsis
(AUC= 0.86 and 0.90, respectively). However, the system-
atic reviews of diagnostic accuracy studies were usually
characterized by significant heterogeneity on account of
the small sample sizes in most studies of plasma NGAL.
Moreover, meta-regression, subgroup analysis, and publi-
cation bias were not performed to identify the sources of
heterogeneity, which made it difficult to interpret the
Diagnostic Odds Ratio
0.01 100.01
Aydogdu 2013 18.33    (7.32 - 45.93)
Fan 2014 24.07    (8.84 - 65.58)
Hjortrup 2015 3.27     (1.28 - 8.35)
Li 2010 114.29   (13.05 - 1,000.55)
Martensson 2010 135.00   (6.94 - 2,624.66)
Niu 2015 44.47    (9.61 - 205.85)
Si 2015 1.49     (0.75 - 2.94)
Wang 2014 36.40    (10.51 - 126.07)
Xing 2013 90.67    (18.81 - 437.05)
Yan 2011 105.75   (26.52 - 421.74)
Yan 2013 37.55    (13.40 - 105.23)
Zhou 2014 14.76    (6.28 - 34.68)
Diagnostic OR (95% CI)
Random Effects Model
Pooled Diagnostic Odds Ratio = 24.20 (9.92 to 59.05)
Cochran-Q = 79.43; df =  11 (p = 0.0000)
























Camou 2013 10.00    (1.49 - 66.99)
de Geus 2013 16.00    (4.82 - 53.13)
Hjortrup 2015 4.47     (1.89 - 10.55)
Martensson 2010 28.75    (5.62 - 147.06)
Shapiro 2010 23.96    (3.22 - 178.48)
Xing 2013 39.60    (10.43 - 150.41)
Diagnostic OR (95% CI)
Random Effects Model
Pooled Diagnostic Odds Ratio = 14.72 (6.55 to 33.10)
Cochran-Q = 10.07; df =  5 (p = 0.0732)























Fig. 4 DOR and SROC curves of plasma and urine NGAL for prediction of septic AKI. a DOR of plasma NGAL for prediction of septic AKI. b DOR
of urine NGAL for prediction of septic AKI. c SROC curve of plasma NGAL for prediction of septic AKI. d SROC curve of urine NGAL for prediction
of septic AKI. AUC area under the curve, CI confidence interval, SROC summary receiver operating characteristic, OR odds ratio, SE standard error
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Table 5 Possible sources of heterogeneity of meta-analysis (results of subgroup analysis and meta-regression analysis)






AUC Coeff. SE P value RDOR (95 % CI)
(95 % CI) (95 % CI) (95 % CI) (95 % CI) (95 % CI)
Setting ICU 10 0.85 (0.81–0.88) 0.82 (0.79–0.85) 4.73 (3.41–6.55) 0.19 (0.12–0.31) 29.05 (14.29–59.02) 0.91 –0.96 1.16 0.45 0.38 (0.02–9.57)
ER 2 0.67 (0.59–0.75) 0.63 (0.52–0.73) 2.56 (0.48–13.65) 0.35 (0.05–2.34) 7.57 (0.27–216.18) –
Design Prospective 7 0.77 (0.73–0.82) 0.76 (0.71–0.80) 3.41 (1.98–5.85) 0.24 (0.11–0.50) 15.00 (4.58–49.14) 0.84 0.16 0.80 0.85 1.18 (0.13–10.85)
Nonprospective 5 0.85 (0.79–0.90) 0.87 (0.82–0.90) 6.40 (3.94–10.40) 0.19 (0.11–0.32) 45.65 (18.15–114.83) 0.94
Number of cases ≥100 7 0.87 (0.74–0.82) 0.76 (0.72–0.79) 3.20 (1.95–5.24) 0.24 (0.12–0.49) 13.62 (4.53–40.98) 0.82 1.33 0.84 0.19 3.77 (0.37–38.63)
<100 5 0.85 (0.78–0.91) 0.90 (0.85–0.94) 7.85(5.24–11.74) 0.18 (0.11–0.30) 58.18 (27.63–122.49) 0.95
NGAL test method ELISA 9 0.81 (0.77–0.84) 0.81 (0.77–0.84) 4.79 (2.76–8.32) 0.18 (0.09–0.35) 28.07 (9.47–83.18) 0.91 0.51 1.01 0.64 1.66 (0.10–26.97)
Non-ELISA 3 0.78 (0.69–0.86) 0.77 (0.70–0.83) 3.16 (1.46–6.82) 0.31 (0.12–0.76) 15.56 (2.42–100.09) 0.86
Location Asia 9 0.88 (0.84–0.91) 0.83 (0.79–0.86) 5.01 (3.87–6.49) 0.17 (0.12–0.22) 33.05 (20.72–52.72) 0.92 –1.23 1.30 0.40 0.29 (0.01–10.88)
Others 3 0.63 (0.55–0.70) 0.69 (0.61–0.76) 1.99 (0.83–4.76) 0.56 (0.34–0.93) 4.34 (0.96–19.62) 0.64
Language English 5 0.74 (0.68–0.79) 0.71 (0.65–0.76) 2.51 (1.38–4.57) 0.34 (0.17–0.69) 9.36 (2.40–36.54) 0.83 0.60 1.04 0.59 1.82 (0.10–32.62.)
Chinese 7 0.87 (0.83–0.91) 0.86 (0.82–0.89) 5.77 (4.56–7.30) 0.16 (0.10–0.24) 41.64 (22.82–75.97) 0.93










funnel plots. Meanwhile, for urine NGAL, although the
threshold effect, heterogeneity test, subgroup analysis,
meta-regression, and publication bias were analyzed to
identify potential influencing factors, the cause of non-
threshold effects that induce heterogeneity was not par-
ticularly clear, probably because the differences in
specimen sampling time and cutoff values among these
included studies might have affected the heterogeneity
and further analysis could not be conducted because of
the limitations of the primary studies. Moreover, in some
useful studies 2 × 2 contingency table data could not be
extracted, which also led to bias of the results.
In addition, we noticed some interesting results re-
ported in recent articles. In AKI patients, Bagshaw et al.
[46] conducted a comprehensive observational study to
assess the prospective evaluation of NGAL in septic vs.
nonseptic AKI. The AUC of plasma NGAL (≥280 ng/ml)
for the diagnosis of septic vs. non-septic AKI was 0.77
(95 % CI: 0.63–0.90) with a sensitivity of 0.75 and speci-
ficity of 0.76, while that of urine NGAL (≥150 ng/mg
creatinine) was 0.70 (95 % CI: 0.59–0.82) with a sensitiv-
ity of 0.69 and specificity of 0.60 for a diagnosis of septic
AKI. The peak plasma NGAL showed fair discriminatory
power for prediction of AKI progression (AUC = 0.71,
95 % CI: 0.55–0.88) and need for RRT (AUC = 0.78,
95 % CI: 0.61–0.95), while urine NGAL performed less
well for prediction of AKI progression (AUC = 0.70,
95 % CI: 0.58–0.81) and need for RRT (AUC = 0.70,
95 % CI: 0.58–0.82), and peak urine NGAL (≥230 ng/mg
creatinine) predicted AKI progression with a sensitivity
of 0.78 and specificity of 0.81, which was better than
compared with septic AKI (AUC = 0.82 vs. 0.59,
respectively; P = 0.04). Peak plasma and urine NGAL
alone had poor discriminatory power for prediction of
in-hospital death (plasma NGAL: AUC = 0.69; 95 % CI:
0.48–0.74; urine NGAL: AUC = 0.62; 95 % CI: 0.49–
0.76) [46]. The study indicated that septic AKI patients
had higher detectable NGAL compared with nonseptic
AKI patients, but whether there was a correlation be-
tween sepsis and NGAL was unclear. Some scholars
studied the predictive value of NGAL for sepsis. The
AUC of plasma NGAL was 0.51 (95 % CI 0.46–0.56),
even differing from that of procalcitonin (0.67, 95 % CI
0.62–0.72, P <0.01) in a prospective observational study
[47]. High plasma NGAL was also observed that could
independently predict mortality (AUC = 0.64) and mul-
tiple organ dysfunction syndrome in severe sepsis and
septic shock during ICU stay (hazard ratio = 2.13; 95 %
CI: 1.08–4.20; P = 0.03 and hazard ratio = 1.90; 95 % CI:
1.01–3.55; P = 0.046, respectively) [48]. In several pro-
spective studies, NGAL levels were significantly higher
among septic patients than nonseptic subjects, but the
precise influence of the diagnostic test characteristics re-
mains unclear [33, 46, 49].
A prospective single-center cohort study that included
663 admissions to the ICU found that the AUC of peak
plasma NGAL values for AKI was unaffected by the
presence of sepsis (0.78, 95 % CI: 0.67–0.86 for sepsis vs.
0.76, 95 % CI: 0.72–0.79 for nonsepsis; P = 0.72) [34].
Meanwhile, during sepsis, plasma NGAL was moderately
to strongly correlated with cytokine interleukin (IL)-6 in
septic patients and animal models, which clarified that
plasma NGAL might be involved in immune responses
during inflammation, rather than only restricted to the
Fig. 5 Deeks Funnel plot assessment of potential publication bias. Each solid rectangle represents an eligible study. ESS effective sample size
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diagnosis of AKI. Nevertheless, in sepsis with AKI,
plasma NGAL and tumor necrosis factor alpha (TNFα)
were already elevated at 6 hours without changes to
serum creatinine and blood urea nitrogen, while IL-6
and IL-10 are increased only after 24 hours. This
phenomenon indicated that the early increase of plasma
NGAL during sepsis was not solely a result of inflamma-
tion and cytokine storm but rather results from early
kidney damage, which revealed the predictive value of
early diagnosis of sepsis AKI. The association of TNFα
with NGAL showed that septic AKI might be mainly ini-
tiated by TNFα, also explaining why higher NGAL levels
were found in septic vs. nonseptic AKI [50].
Conclusion
Early and efficient diagnosis of AKI is of great signifi-
cance to the prognosis of critically ill patients. In conclu-
sion, to a certain extent, NGAL is not only an effective
predictive factor for AKI in the process of sepsis, but
also shows potential predictive value for RRT and mor-
tality. The results of the current study motivated us to
reconsider the value of NGAL for prediction of AKI in
septic patients. More future trials with larger sample
sizes and high-quality evidence are needed to clarify this
controversial issue for further improvement of patient
outcomes.
Key messages
 AKI is a widespread problem in critically ill patients,
and sepsis is a well-known precipitating factor for
the development of AKI.
 NGAL is not only an effective predictive factor for
AKI in the process of sepsis, but also shows
potential value for RRT and mortality.
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